CPT® Code 38226

Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)

Chimeric antigen receptor T-cell (CAR-T) therapy represents a groundbreaking approach in the field of immunotherapy, utilizing the patient's own immune cells, specifically T-lymphocytes, to combat cancer. This innovative treatment involves a complex process where T-cells are extracted from the patient's blood and subsequently modified in a laboratory setting. The modification is achieved through the introduction of a disarmed virus that carries genetic material, enabling the T-cells to express chimeric antigen receptors (CARs) on their surface. These CARs are crucial as they empower the T-cells to identify and bind to specific protein antigens present on the surface of cancer cells, thereby facilitating targeted destruction of these malignant cells. The procedure begins with the withdrawal of blood from the patient, which may occur over several days, allowing for the separation of T-lymphocytes. Once isolated, these T-cells undergo genetic engineering to produce CARs, and they are then expanded to generate a substantial quantity, often numbering in the hundreds of millions. During this manufacturing phase, the patient typically receives lymphocytic cell-depleting chemotherapy to prepare their immune system for the subsequent infusion of the modified T-cells. After the CAR-T cells are fully prepared, they are reintroduced into the patient's body, where they seek out and eliminate cancer cells. The CAR-T cells are designed to remain active within the body for an extended period, providing ongoing surveillance against potential cancer recurrence. The specific CPT® code 38226 pertains to the preparation of these blood-derived T lymphocytes for transportation, which includes processes such as cryopreservation and storage following their initial harvesting.